Developer docs
API playgroundTry for free, no card

Search company profiles

ViewRay

Full company profile

uuid0004jim

Namestring
ViewRay
Legal namestring
ViewRay Systems, Inc.
Websiteurl
viewray.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

ViewRay Systems, Inc. designs, manufactures, and sells the MRIdian A3i, an MRI-guided radiation therapy system that integrates diagnostic-quality MRI imaging with real-time radiation delivery in a single platform. The company's core technology combines high-field MRI for soft-tissue visualization with automated beam gating and tissue tracking, enabling clinicians to deliver ablative radiation doses with greater precision than conventional radiotherapy systems that rely on implanted markers. The system is positioned for the treatment of pancreatic, prostate, lung, liver, breast, and oligometastatic cancers.

The company sells its systems directly to hospitals and cancer treatment centers worldwide through an enterprise field sales motion, supplemented by clinical webinars, scientific presentations, and patient advocacy content targeting radiation oncologists. Revenue is generated primarily through capital equipment sales of the MRIdian A3i system, with an overlaid recurring service and support revenue stream managed through a dedicated customer portal. Founded in 2004 and headquartered in Oakwood Village, Ohio, ViewRay has raised approximately $700 million+ in cumulative equity and debt financing across multiple rounds since 2008, with the most recent being a $125 million debt facility from MidCap Financial and Silicon Valley Bank in November 2022. The radiotherapy market in which ViewRay operates was approximately $10.2 billion in 2024 and is projected to grow at a 4.2% CAGR to $12.5 billion by 2029, against larger competitors including Elekta, Siemens Healthineers, GE HealthCare, Canon Medical Systems, and Accuray.

Short descriptiontext

ViewRay Systems designs and sells the MRIdian A3i, an MRI-guided radiation therapy system that combines diagnostic MRI imaging with real-time beam control for precise cancer treatment. It sells directly to hospitals and cancer treatment centers worldwide as capital equipment.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersOakwood, United States
HQ citystring
Oakwood
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
MRI-guided radiotherapy, radiation therapy systems, cancer treatment equipment, medical imaging devices, radiotherapy capital equipment
Industry3 codes
1Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim)
CodeHLAHABAHPrimaryYes
2Magnetic Resonance Imaging (MRI) Systems
CodeHLAHABACPrimaryNo
3Radiation Oncology
CodeHLAKAFACPrimaryNo
NAICS code1 code
  • Irradiation Apparatus Manufacturing334517
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Radiation Therapy Systems
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1MRI-Guided Radiotherapy Systems (Capital Equipment)
TypeHardware Sales
Description

ViewRay generates revenue primarily from the sale of MRIdian A3i radiotherapy systems to hospitals and cancer treatment centers. Medical device capital equipment sales with typically long sales cycles involving clinical validation and procurement processes.

viewraysystems.com
2Service and Support Contracts
TypeSubscription Recurring
Description

Ongoing service contracts and support for installed systems, implied by the Customer Portal access and treatment center network.

viewraysystems.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1MRIdian A3i
Description

MRI-guided radiation therapy system designed for precise cancer treatment with real-time tissue tracking and automated beam control.

viewraysystems.com
Core offering1 text field

ViewRay Systems, Inc. develops and sells the MRIdian A3i, an MRI-guided radiation therapy system that integrates diagnostic-quality MRI imaging with linear accelerator-based radiation delivery. The system enables precise tumor contouring, real-time soft-tissue tracking, and automated beam control to deliver ablative radiation doses with reduced side effects across multiple cancer types including pancreatic, prostate, lung, liver, breast, and oligometastatic cancers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Reduced side effects and extended survival demonstrated through peer-reviewed clinical evidence
Product overview1 text field

ViewRay Systems offers the MRIdian A3i, a single MRI-guided radiation therapy system. The MRIdian A3i is the company's core and only product — an MR-guided radiotherapy platform that combines real-time MRI imaging with radiation delivery for precise cancer treatment across multiple cancer types including pancreas, prostate, lung, liver, breast, and oligometastatic cancers.

Product and service1 record
1MRIdian A3i
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swedish maker of linear accelerators, Gamma Knife, and radiation oncology solutions including Unity, an MR-guided radiotherapy system that competes head-to-head with ViewRay's MRIdian A3i. Already a 2019 investor in ViewRay and the most direct peer.

TypeDirect peer
Description

US-based maker of CyberKnife and TomoTherapy radiation therapy systems. Competes with ViewRay in the precision radiotherapy capital equipment market targeting cancer treatment centers.

TypeDirect peer
Description

Radiation oncology and software leader (now part of Siemens Healthineers). Maker of TrueBeam and Halcyon linacs and ARIA oncology software — a foundational competitor in the radiotherapy capital equipment space ViewRay addresses.

TypeEmerging player
Description

Compact proton therapy systems maker. Competes in advanced radiation therapy capital equipment for cancer centers, addressing similar hospital buyers with a different modality.

TypeBroad incumbent
Description

Global medical imaging and oncology equipment giant with MRI systems, linacs (post-Varian acquisition), and comprehensive hospital solutions. Competes broadly in the radiotherapy and imaging capital equipment space.

TypeBroad incumbent
Description

Major medical imaging incumbent with MRI, CT, and radiation oncology offerings. Competes with ViewRay on MRI integration and broader hospital capital equipment purchasing decisions.

TypeBroad incumbent
Description

Imaging and diagnostic equipment maker with MRI, CT, and growing oncology footprint. Competes in hospital imaging capital equipment markets where ViewRay sells MRIdian.

TypeBroad incumbent
Description

Healthcare technology incumbent with diagnostic imaging, image-guided therapy, and oncology informatics. Competes with ViewRay in hospital imaging and image-guided intervention purchasing decisions.

TypeBroad incumbent
Description

Provider of proton beam therapy systems and diagnostic imaging including MRI. Competes in advanced radiotherapy capital equipment markets alongside ViewRay.

TypeEmerging player
Description

Software-driven image-guided surgery and radiotherapy planning vendor. Provides oncology informatics and treatment planning software that complements or competes with elements of the MRIdian workflow at cancer centers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds21 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ViewRay

Radiation Therapy Systemsviewray.com

ViewRay Systems designs and sells the MRIdian A3i, an MRI-guided radiation therapy system that combines diagnostic MRI imaging with real-time beam control for precise cancer treatment. It sells directly to hospitals and cancer treatment centers worldwide as capital equipment.

What ViewRay does

ViewRay Systems, Inc. designs, manufactures, and sells the MRIdian A3i, an MRI-guided radiation therapy system that integrates diagnostic-quality MRI imaging with real-time radiation delivery in a single platform. The company's core technology combines high-field MRI for soft-tissue visualization with automated beam gating and tissue tracking, enabling clinicians to deliver ablative radiation doses with greater precision than conventional radiotherapy systems that rely on implanted markers. The system is positioned for the treatment of pancreatic, prostate, lung, liver, breast, and oligometastatic cancers.

The company sells its systems directly to hospitals and cancer treatment centers worldwide through an enterprise field sales motion, supplemented by clinical webinars, scientific presentations, and patient advocacy content targeting radiation oncologists. Revenue is generated primarily through capital equipment sales of the MRIdian A3i system, with an overlaid recurring service and support revenue stream managed through a dedicated customer portal. Founded in 2004 and headquartered in Oakwood Village, Ohio, ViewRay has raised approximately $700 million+ in cumulative equity and debt financing across multiple rounds since 2008, with the most recent being a $125 million debt facility from MidCap Financial and Silicon Valley Bank in November 2022. The radiotherapy market in which ViewRay operates was approximately $10.2 billion in 2024 and is projected to grow at a 4.2% CAGR to $12.5 billion by 2029, against larger competitors including Elekta, Siemens Healthineers, GE HealthCare, Canon Medical Systems, and Accuray.

ViewRay firmographics

Firmographics
Name
ViewRay
Legal name
ViewRay Systems, Inc.
Website
https://viewray.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
51–100 employees
Short description
ViewRay Systems designs and sells the MRIdian A3i, an MRI-guided radiation therapy system that combines diagnostic MRI imaging with real-time beam control for precise cancer treatment. It sells directly to hospitals and cancer treatment centers worldwide as capital equipment.
Ownership category
akta.pro rank

ViewRay industry classification

Industry
Product category
Radiation Therapy Systems
NAICS
Irradiation Apparatus Manufacturing (334517)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH)
akta.pro secondary industries
Magnetic Resonance Imaging (MRI) Systems (HLAHABAC), Radiation Oncology (HLAKAFAC)

Keywords

  • MRI-guided radiotherapy
  • Radiation therapy systems
  • Cancer treatment equipment
  • Medical imaging devices
  • Radiotherapy capital equipment

Where ViewRay is headquartered

Location

Headquarters

HQ city
Oakwood
HQ country
United States
HQ region
North America

Offices3 records

Markets served

ViewRay business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. MRI-Guided Radiotherapy Systems (Capital Equipment): ViewRay generates revenue primarily from the sale of MRIdian A3i radiotherapy systems to hospitals and cancer treatment centers. Medical device capital equipment sales with typically long sales cycles involving clinical validation and procurement processes.
  2. Service and Support Contracts: Ongoing service contracts and support for installed systems, implied by the Customer Portal access and treatment center network.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

ViewRay product offering

Product offering

Core offering

ViewRay Systems, Inc. develops and sells the MRIdian A3i, an MRI-guided radiation therapy system that integrates diagnostic-quality MRI imaging with linear accelerator-based radiation delivery. The system enables precise tumor contouring, real-time soft-tissue tracking, and automated beam control to deliver ablative radiation doses with reduced side effects across multiple cancer types including pancreatic, prostate, lung, liver, breast, and oligometastatic cancers.

Product overview

ViewRay Systems offers the MRIdian A3i, a single MRI-guided radiation therapy system. The MRIdian A3i is the company's core and only product — an MR-guided radiotherapy platform that combines real-time MRI imaging with radiation delivery for precise cancer treatment across multiple cancer types including pancreas, prostate, lung, liver, breast, and oligometastatic cancers.

Differentiator

Problem solved

Functional benefit

Brands

  • MRIdian A3i: MRI-guided radiation therapy system designed for precise cancer treatment with real-time tissue tracking and automated beam control.

Products and services

  • MRIdian A3i

Quantifiable outcome

  • Reduced side effects and extended survival demonstrated through peer-reviewed clinical evidence

Companies that use ViewRay

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

ViewRay technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

ViewRay partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

ViewRay competitors and assessment

Company assessment

Direct peers

  • Elekta: Swedish maker of linear accelerators, Gamma Knife, and radiation oncology solutions including Unity, an MR-guided radiotherapy system that competes head-to-head with ViewRay's MRIdian A3i. Already a 2019 investor in ViewRay and the most direct peer.
  • Accuray: US-based maker of CyberKnife and TomoTherapy radiation therapy systems. Competes with ViewRay in the precision radiotherapy capital equipment market targeting cancer treatment centers.
  • Varian Medical Systems: Radiation oncology and software leader (now part of Siemens Healthineers). Maker of TrueBeam and Halcyon linacs and ARIA oncology software — a foundational competitor in the radiotherapy capital equipment space ViewRay addresses.

Emerging players

  • Mevion Medical Systems: Compact proton therapy systems maker. Competes in advanced radiation therapy capital equipment for cancer centers, addressing similar hospital buyers with a different modality.
  • Brainlab: Software-driven image-guided surgery and radiotherapy planning vendor. Provides oncology informatics and treatment planning software that complements or competes with elements of the MRIdian workflow at cancer centers.

Broad incumbents

  • Siemens Healthineers: Global medical imaging and oncology equipment giant with MRI systems, linacs (post-Varian acquisition), and comprehensive hospital solutions. Competes broadly in the radiotherapy and imaging capital equipment space.
  • GE HealthCare: Major medical imaging incumbent with MRI, CT, and radiation oncology offerings. Competes with ViewRay on MRI integration and broader hospital capital equipment purchasing decisions.
  • Canon Medical Systems: Imaging and diagnostic equipment maker with MRI, CT, and growing oncology footprint. Competes in hospital imaging capital equipment markets where ViewRay sells MRIdian.
  • Philips: Healthcare technology incumbent with diagnostic imaging, image-guided therapy, and oncology informatics. Competes with ViewRay in hospital imaging and image-guided intervention purchasing decisions.
  • Hitachi (Medical Systems): Provider of proton beam therapy systems and diagnostic imaging including MRI. Competes in advanced radiotherapy capital equipment markets alongside ViewRay.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

ViewRay social profiles

Digital presence

ViewRay financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ViewRay leadership team

Management profile

Number of profiles

Profiles7 records

ViewRay funding detail

Funding detail

Funding overview

Funding rounds21 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ViewRay M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ViewRay

What does ViewRay do?

ViewRay Systems, Inc. develops and sells the MRIdian A3i, an MRI-guided radiation therapy system that integrates diagnostic-quality MRI imaging with linear accelerator-based radiation delivery. The system enables precise tumor contouring, real-time soft-tissue tracking, and automated beam control to deliver ablative radiation doses with reduced side effects across multiple cancer types including pancreatic, prostate, lung, liver, breast, and oligometastatic cancers.

Is ViewRay a public or private company?

ViewRay is a private company. It is classified as public and is currently operating.

When was ViewRay founded?

ViewRay was founded in 2004. It employs 51 to 100 people.

Where is ViewRay based?

ViewRay is headquartered in Oakwood, United States, in the North America region.

How does ViewRay make money?

Two revenue lines are on record. MRI-Guided Radiotherapy Systems (Capital Equipment) is the primary driver. The others are service and Support Contracts.

Who are ViewRay's main competitors?

Direct peers on record are Elekta, Accuray and Varian Medical Systems. Emerging players are Mevion Medical Systems and Brainlab. Broad incumbents are Siemens Healthineers, GE HealthCare, Canon Medical Systems, Philips and Hitachi (Medical Systems).

Does ViewRay have an API?

No public API is recorded for ViewRay.

What industry is ViewRay in?

ViewRay's product category is Radiation Therapy Systems. Its primary akta.pro industry code is HLAHABAH, Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim), with a secondary code of HLAHABAC, Magnetic Resonance Imaging (MRI) Systems. Its NAICS code is 334517 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Market ScoopTreatment Planning Systems And Advanced Image Processing MarketA market research report published in February 2024 projects the global Treatment Planning Systems and Advanced Image Processing Market to grow from USD 1989.1 million in 2023 to USD 4539 million by 2033, at a CAGR of 8.6%. North America led the market in 2023 with a 38.4% share, driven by advanced infrastructure and high cancer prevalence. Key industry players highlighted include Elekta AB, Koninklijke Philips NV, and ViewRay Inc., which recently received FDA clearance for its MRIdian Linac system.GlobeNewswireDelisting of Securities of Nymox Pharmaceutical Corporation; Aridis Pharmaceuticals Inc.; Novan, Inc.; ViewRay, Inc.; 9 Meters Biopharma, Inc.; Nabriva Therapeutics plc; UTA Acquisition Corporation; ANasdaq announced delisting of securities for Nymox Pharmaceutical, Aridis Pharmaceuticals, Novan, ViewRay, 9 Meters Biopharma, Nabriva Therapeutics, UTA Acquisition, AppHarvest, Yellow Corporation, Proterra, Amyris, Chain Bridge I, LatAmGrowth SPAC, and SpringBig Holdings. Each company's securities were suspended in July or August 2023 and had not traded since.BenzingaDomino's Pizza, Whirlpool And 3 Stocks To Watch Heading Into Monday - Contango Silver & Gold (AMEX:CTGO),The article previews stock market activity for Monday, highlighting earnings reports and corporate developments for Domino's Pizza, Whirlpool Corporation, ViewRay, Inc., Contango Ore, Inc., and NXP Semiconductors. Key events include ViewRay's Nasdaq delisting proceedings, Contango Ore's undisclosed public offering, and scheduled quarterly earnings releases for the other listed entities.BenzingaWhy ViewRay Stock Hit A New 52-Week Low TodayViewRay Inc (NASDAQ:VRAY) shares fell 13% to $0.07 on Tuesday, hitting a new 52-week low after the company filed voluntary Chapter 11 bankruptcy petitions. ViewRay has secured approximately $6 million in debtor-in-possession financing and plans to sell its business and assets while maintaining customer operations and inventory. The company also announced board resignations and appointed Paul Ziegler as new CEO as it seeks to deliver value to cancer patients and stakeholders.BenzingaUS Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July - Acumen Pharmaceuticals (NASDAQU.S. stocks edged higher on Monday with the Dow, NASDAQ, and S&P 500 posting modest gains, while the NY Empire State Manufacturing Index fell to +1.1 in July, beating market estimates. In biotech trading, ProMIS Neurosciences and BridgeBio Pharma surged following positive clinical data presentations, whereas Novan and ViewRay plummeted after filing for Chapter 11 bankruptcy protection.BenzingaTop 5 Health Care Stocks That Could Blast Off In May - Coherus Oncology (NASDAQ:CHRS)This article profiles five oversold healthcare stocks based on RSI (Relative Strength Index) indicators below 30, presenting them as potential buying opportunities. YS Biopharma secured Phase 3 clinical trial approval for its PIKA Rabies vaccine in Pakistan; Intercept Pharmaceuticals faced an FDA advisory committee vote (12-2) that its Ocaliva drug benefits don't outweigh risks in NASH patients; ViewRay reported worse-than-expected quarterly revenue, withdrew guidance, and announced it's evaluating strategic alternatives including a potential sale or merger with Goldman Sachs advisory support; Coherus BioSciences launched its UDENYCA autoinjector in the U.S. market; and Surmodics posted stronger-than-expected quarterly earnings with 7% year-over-year growth in its Medical Device segment.PR NewswireViewRay's MRIdian® to be Featured at Leading European Radiation Oncology MeetingViewRay, Inc. announced that its MRIdian MRI-guided radiation therapy system will be featured at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO) in Vienna, Austria, with over 50 clinical presentations highlighting its use. The company will host a symposium showcasing the new MRIdian A3i features, which enhance adaptive workflow efficiency and real-time tissue tracking capabilities. This event underscores ViewRay's ongoing promotion of its technology to global oncology professionals.BenzingaInternational Game Technology To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Thursday - ProMultiple financial institutions, including Goldman Sachs, Wells Fargo, and Morgan Stanley, adjusted their price targets and analyst ratings for various publicly traded companies ahead of Thursday's market open. The updates included upgrades for International Game Technology and J.B. Hunt Transport, while ViewRay and ProFrac Holding faced downgrades and significant price target cuts. These analyst revisions reflect shifting sentiment across sectors ranging from gaming and logistics to real estate and agriculture.PR NewswireViewRay Announces First Quarter 2023 ResultsViewRay, Inc. reported first quarter 2023 financial results with total revenue of $22.5 million, up from $18.9 million in Q1 2022, while net loss widened to $28.9 million from $25.8 million year-over-year. The company announced it is evaluating strategic alternatives including a potential corporate sale or merger with Goldman Sachs as financial advisor, while simultaneously implementing a cost reduction program targeting $19-23 million in annual savings, including an 11% workforce reduction. CFO Bill Burke stepped down and will be replaced by Jake Signoriello as interim CFO, and the company withdrew its previously issued financial guidance for fiscal year 2023.PR NewswireViewRay Announces Conference Call for First Quarter 2023 Financial Results to be Held After Market on May 10, 2023ViewRay, Inc. announced details for the release of its first quarter 2023 financial results, scheduled for May 10, 2023, along with a conference call at 4:30 p.m. ET to discuss the results. The announcement provided dial-in numbers and confirmed that a live webcast would be available on the company's investor relations website. ViewRay designs, manufactures, and markets the MRIdian MR-Guided Radiation Therapy System for advanced radiation oncology.